- Home
- BTMD vs LPTX Comparison
BTMD vs LPTX Comparison
Compare BTMD & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTMD
- LPTX
- Stock Information
- Founded
- BTMD 2012
- LPTX 2011
- Country
- BTMD United States
- LPTX United States
- Employees
- BTMD N/A
- LPTX N/A
- Industry
- BTMD Medicinal Chemicals and Botanical Products
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTMD Health Care
- LPTX Health Care
- Exchange
- BTMD Nasdaq
- LPTX Nasdaq
- Market Cap
- BTMD 129.1M
- LPTX 119.6M
- IPO Year
- BTMD N/A
- LPTX N/A
- Fundamental
- Price
- BTMD $4.06
- LPTX $0.32
- Analyst Decision
- BTMD Strong Buy
- LPTX Hold
- Analyst Count
- BTMD 1
- LPTX 1
- Target Price
- BTMD $8.00
- LPTX N/A
- AVG Volume (30 Days)
- BTMD 135.1K
- LPTX 3.3M
- Earning Date
- BTMD 08-07-2025
- LPTX 08-11-2025
- Dividend Yield
- BTMD N/A
- LPTX N/A
- EPS Growth
- BTMD 201.68
- LPTX N/A
- EPS
- BTMD 0.60
- LPTX N/A
- Revenue
- BTMD $199,379,000.00
- LPTX N/A
- Revenue This Year
- BTMD $5.87
- LPTX N/A
- Revenue Next Year
- BTMD $8.59
- LPTX N/A
- P/E Ratio
- BTMD $6.77
- LPTX N/A
- Revenue Growth
- BTMD 6.44
- LPTX N/A
- 52 Week Low
- BTMD $3.04
- LPTX $0.22
- 52 Week High
- BTMD $8.44
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- BTMD 52.67
- LPTX 45.72
- Support Level
- BTMD $3.92
- LPTX $0.28
- Resistance Level
- BTMD $4.23
- LPTX $0.32
- Average True Range (ATR)
- BTMD 0.19
- LPTX 0.04
- MACD
- BTMD -0.01
- LPTX -0.00
- Stochastic Oscillator
- BTMD 38.18
- LPTX 31.70
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .